First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report

First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report

ABSTRACT Background Epidermal growth factor receptor (EGFR) mutations in squamous cell lung carcinoma are rare. EGFR‐tyrosine kinase inhibitors are generally less effective for EGFR‐mutated squamous cell lung carcinoma. We herein present a case of EGFR‐mutated squamous cell lung carcinoma that respo...

Full description

Saved in:
Bibliographic Details
Main Authors: Yugo Matsumura, Seiya Ichihara, Kaori Nii, Kazumasa Nanjo, Naoki Kadota, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Hiroyuki Hino, Keishi Naruse, Tsutomu Shinohara, Shoji Sakiyama, Eiji Tacheuchi
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Cancer Reports
Subjects:
EGFR mutation
EGFR‐TKI
L858R
osimertinib
squamous cell lung cancer
Online Access:https://doi.org/10.1002/cnr2.70273
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cnr2.70273

Similar Items